Hodgkins disease by Ferme, C et al.
The development of extended-field radiotherapy, of chemotherapy
and then of the combination of the two therapeutic modalities, has
led to cure rates of almost 80% in patients with Hodgkins disease
(HD). The aim of management in patients presenting with HD
must no longer be cure alone, but cure without sequelae and with
the best possible quality of life. Further efforts are necessary to
reduce the long-term toxicity of treatment and to improve the
prognosis of recurrent disease and that resistant to standard
treatment. Numerous questions remain unanswered regarding the
heterogeneous histology and phenotypes of the disease and
the diversity of the clinical presentations. 
This document does not apply to patients who develop HD as a
consequence of HIV disease. Similarly, the management of
patients with nodular lymphocyte-predominant HD (paragranu-
loma of Poppema), which is considered to be a different entity
than HD, is not considered. 
The SOR document on the management of HD in adults was
published in full in 1998. An update is planned for the year 2001.
It will deal in particular with: 
l the best combinations of radiochemotherapy and the move
away from radiotherapy as single-modality treatment for stage
I–II supradiaphragmatic disease 
l the role of international prognostic scores in the development
of treatment strategies for disseminated disease 
l the indications and the best modalities for irradiation in the
treatment of advanced disease. 
DIAGNOSIS 
The diagnosis of HD depends on the histological examination of a
biopsy and the identification of Reed–Sternberg cells (standard). A
cytological diagnosis alone is not acceptable. The use of immune
markers is necessary for the differential diagnosis in lymphocyte-
predominant types (CD30, CD15, CD45, EMA, CD20). It is
recommended for other forms, such as lymphocyte-depleted types
(CD30, CD45, EMA, T and B markers) of the Lukes–Rye classifi-
cation (option), in order not to misdiagnose anaplastic large cell
lymphoma. In difficult cases, review by a specialist pathologist is
recommended. 
STAGING 
Accurate initial staging is essential in order to classify patients into
groups according to specific prognostic factors that define the
treatment strategy. 
The clinical history provides information about systemic symp-
toms (fever, sweats and weight loss) that are essential for the
classification of the disease (standard). Clinical examination must
detect any site of superficial lymphadenopathy, as well as any
hepato- or splenomegaly (standard). 
Assessment of the chest should include a chest X-ray (AP and
lateral) and a thoracic CT scan (standard). A large mediastinal mass
is defined as that having a diameter equal or greater than a third of
the transverse diameter of the chest at the level of the T5–T6 disc
interspace, from a thoracic film taken AP with the patient standing
(standard). The place of MRI in the staging of disease in the chest
remains to be determined and it must only be used within a trial
setting. Routine gallium scans are not indicated during initial staging
(level of evidence C). A baseline image of a large mediastinal mass
using SPECT (single photon emission computed tomography) can
be used to evaluate subsequent response to treatment. 
Examination of Waldeyer’s ring by a specialist is indicated in
cases where there is high cervical lymphadenopathy (standard). 
An abdomino-pelvic CT scan is used to detect sub-
diaphragmatic disease (standard). A bipedal lymphangiogram and
an abdominal ultrasound (option) can provide additional informa-
tion to that gained from CT scanning. There is no consensus as to
the routine use of bipedal lymphography in diagnostic staging
(level of evidence C). No study has evaluated the impact of the
addition of lymphangiography to CT scanning on treatment deci-
sions. A lymphangiogram is recommended for localized disease
where the result would have an impact on treatment planning, in
particular when CT scanning has not shown any involvement of
sub-diaphragmatic nodes. The interpretation of lymphangiograms
requires specialist experience. If imaging has demonstrated focal
liver lesions of uncertain aetiology, a guided-needle biopsy under
CT or ultrasound control is indicated (option). Ultrasonography is
less accurate than CT scanning. 
The place of MRI in abdominal staging remains to be deter-
mined. Any evaluation of the sensitivity and specificity of MRI
and its impact on treatment planning must also consider cost.
Gallium scanning has only a limited role in the evaluation of sub-
diaphragmatic disease (level of evidence B). 
A bone marrow biopsy should be undertaken routinely in
advanced-stage disease and limited-stage disease with
unfavourable prognostic factors (standard). A bone marrow biopsy
is optional in limited-stage disease with favourable prognostic
factors. In advanced-stage disease, with involvement above and
below the diaphragm and/or the presence of systemic symptoms
(B symptoms), bone involvement can be investigated with scintig-
raphy (gallium or technetium bone scan) or by MRI (level of
evidence C). The place of MRI in the investigation of bone
marrow involvement remains to be evaluated. 
The value of any blood test will depend on its prognostic value
and whether or not it will alter treatment decisions. Routine blood
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function and serology for HIV (standard). Lactic dehydrogenase
(LDH) or B2-microglobulin levels and protein electrophoresis
(option) can be undertaken in advanced-stage disease or within a
therapeutic trial. 
Initial staging is completed by other baseline investigations
necessary prior to treatment with chemotherapy or radiotherapy.
Sperm cryopreservation must be considered routinely when
chemotherapy or infradiaphragmatic radiotherapy is to be given
(standard). 
There is no longer any indication for an exploratory laparotomy
with splenectomy (standard) (level of evidence B). It can be
considered in certain circumstances when the information gained
would change the treatment plan, notably if there is doubt




Staging is based on the ‘Cotswold’ modifications of the Ann
Arbor classification (standard). HD can be classified as limited
(stage I and II, above or below the diaphragm) or extensive (stage
III or IV disease) (standard). 
Patients are categorized into therapeutic groups according to
both stage and prognostic factors (standard). Limited-stage disease
above the diaphragm can be stratified into ‘favourable’ and
‘unfavourable’ groups according to the following prognostic
factors: age, number of nodal sites involved, ESR, B symptoms
and the existence or absence of a large nodal mass (level of
evidence B). 
Extensive-stage disease can be differentiated into stages IIIA,
IIIB and IV (standard). The relevant prognostic factors for stage
IIIA disease are age, ESR, the extent of abdominal involvement,
splenic disease and the number of sites involved (level of evidence
C). The prognostic factors used to plan treatment for stages IIIB
and IV disease in therapeutic trials (as recommended by the
FNCLCC, the French Adult Lymphoma Study Group (GELA) and
the French Bone Marrow Transplantation Group) are: anaemia,
level of serum lactate dehydrogenase, inguinal node involvement,
large-volume mediastinal disease (defined as a tumour mass ratio




Surgery no longer has a therapeutic role in the management of HD
(standard). Surgical biopsy is essential (standard). Exploratory
laparotomy with splenectomy is no longer routine practice
(standard); for limited-stage disease, it carries no benefit in terms
of long-term survival (level of evidence B). The decision to
undertake aggressive treatment for patients presenting with bad
prognosis disease is independent of the results of a laparotomy/
splenectomy (level of evidence C). 
Radiotherapy 
Radiotherapy planning must be adapted to the patient and the
volume to be treated (standard). For classic ‘extended volume’
fields (mantle, inverted Y, para-aortic plus spleen) photon beam
energy of 10–25 Mv from a linear accelerator is recommended for
stage I and II supradiaphragmatic disease. The use of Cobalt is not
recommended for mantle irradiation or inverted Y fields in adult
patients. Supra-diaphragmatic mantle irradiation includes the
bilateral cervical and supraclavicular areas, bilateral axillae, the
medias  and pulmonary hila (standard). Subdiaphragmatic inverted
Y irradiation includes the para-aortic, bilateral external iliac and
the bilateral inguinal areas (standard). Irradiation of the para-aortic
lymph nodes and spleen (option) is indicated when the iliac and
inguinal regions are not to be irradiated, thus sparing the ovaries
and the bone marrow (standard). 
Treatment volumes can be reduced or increased in certain clin-
ical circumstances (option). After chemotherapy, radiotherapy
fields can often be reduced to cover only those areas initially
involved (level of evidence C). The doses delivered are those of
the ICRU 50 report (standard). If radiotherapy is given as sole
treatment, the appropriate dose is 40 Gy to involved areas and
30–36 Gy for ‘prophylactic’ treatment (level of evidence C). After
chemotherapy, the dose to areas initially involved is 36 Gy after
complete remission and 40 Gy following incomplete remission
(level of evidence C). 
When there has been no initial mediastinal involvement, the
dose to the inferior mediastinum for subtotal nodal irradiation
following chemotherapy is reduced to 30 Gy (level of evidence C).
It is not recommended to lower the total dose of irradiation except
within a therapeutic trial evaluating dose reduction (level of
evidence C). 
The standard dose rate is 9–10 Gy per week, in five fractions
(standard). The recommended dose per fraction is 1.8–2 Gy (level
of evidence B). The dose per fraction must not exceed 2 Gy (stan-
dard, level of evidence B). 
Large fields are irradiated in two planes treated in the same
session; antero-posterior and posterior-anterior. If at all possible,
dosimetry must ensure maximum homogeneity within the treated
volume to avoid heterogeneous treatment which could result in an
overdose to certain areas with doses per fraction above 2 Gy
(standard). Quality control is mandatory. 
Control films should be taken once a week. The minimum
requirement is two films during the course of treatment (standard).
Custom shielding blocks must be individualized and focused on
the relevant area (standard). The patient is treated in the dorsal
decubitus position (standard). The ventral decubitus position is not
recommended. 
Chemotherapy 
Several chemotherapy protocols have proven efficacy:
MOPP/ABV (nitrogen mustard, vincristine, procarbazine,
prednisone/doxorubicin, bleomycin, vinblastine), MOPP/ABVD
(nitrogen mustard, vincristine, procarbazine, prednisone/doxoru-
bicin, bleomycin, vinblastin, dacarbazine), ABVD (doxorubicin,
bleomycin, vinblastin, dacarbazine), CVPP (cyclophospha-
mide, vinblastin, procarbazine, prednisone), BCVPP (carmustine,
cyclophosphamide, vinblastin, procarbazine, prednisone) and
LOPP (chorambucil, vincristine, procarbazine, prednisone)
(options). 
The results obtained with ABVD are comparable or superior to
those obtained with MOPP, with less long-term toxicity
(secondary leukaemia, sterility) (level of evidence B). The proto-
cols containing seven or eight drugs are superior to MOPP (level
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evidence B). 
The ABVD protocol is considered by a number of groups to be
the reference chemotherapy. It is recommended that centres
become familiar with the use of one protocol (level of evidence B). 
Late toxicity 
The two most important complications which can cause late deaths
in patients cured after treatment of HD are cardiac (myocardial
infarction) and second cancers (leukaemia and solid tumours). The
onset of hypothyroidism may be very late. It is important to inform
patients before treatment about the potential acute, median-term
and long-term toxicities (standard). 
Limiting the dose to the lower mediastinum to 30 Gy, or
excluding this area completely from the irradiation field, is
recommended if at all possible in order to reduce the risk of late
myocardial infarction (level of evidence C). 
Ovariopexy should be undertaken routinely before iliac irradia-
tion in young women (standard). The inclusion of patients in
therapeutic trials evaluating the possibility of reducing therapy in
order to reduce late toxicity is recommended (level of evidence B). 
THERAPEUTIC STRATEGY 
Stage I and II supra-diaphragmatic disease ‘favourable’
group 
Current studies are evaluating sub-total nodal irradiation and
chemoradiotherapy combinations for the treatment of this group
(Figure 1, left arm). While survival rates are equivalent (level of
evidence B), the incidence of long-term complications might
favour protocols with a reduced number of cycles of chemotherapy
and limited radiotherapy as compared to irradiation alone (level of
evidence C). The indication for chemotherapy alone remains
controversial (level of evidence C). 
It is recommended that patients are included in trials evaluating
less toxic protocols, with a reduction in both the number of courses
of chemotherapy and/or the dose of radiotherapy (level of
evidence C). 
Stage I and II supra-diaphragmatic disease
‘unfavourable’ group 
The standard treatment is combination chemoradiotherapy (Figure 1,
right arm). Irradiation alone is not recommended (level of
evidence C). The recommended treatment is six courses of
chemotherapy followed by irradiation to initially involved sites
(level of evidence B). The inclusion of patients in therapeutic trials
evaluating the optimal combination of treatment modalities is
recommended. 
Stage I and II sub-diaphragmatic disease 
The frequency of bad prognostic factors in patients with stage I
and II disease below the diaphragm (as defined for the
unfavourable group of stages I and II supra-diaphragmatic disease)
justifies the use of combination chemo- and radiotherapy as stan-
dard treatment (i.e. six courses of chemotherapy followed by irra-
diation to original disease sites) (level of evidence C) (Figure 2).
Laparotomy with splenectomy does not alter the therapeutic
strategy (level of evidence C), but may be of value in certain
specific cases. For clinical stage IA inguino-femoral disease
without bad prognostic features, irradiation alone (inverted Y plus
spleen) can be considered (option, level of evidence C). 
Stage IIIA disease 
Prognostic factors such as the extent of abdominal nodes, the
volume of involved nodes (defined according to the Cotswold
classification), the age and the ESR, determine treatment for stage
IIIA disease (level or evidence B) (Figures 3 and 4). For patients
with stage IIIA with no unfavourable features (stage IIIA, age less
than 50 years, ESR less than 50 mm h–1 and the absence of large
volume disease), three therapeutic protocols can be considered
(options): 
l subtotal nodal irradiation (level of evidence C) 
l combination chemoradiotherapy with 3–4 courses of
chemotherapy followed by irradiation to sites of initial disease
(level of evidence B) 
l chemotherapy alone (six courses) provided there is an early
complete remission. 
For patients with stage IIIA disease with unfavourable features,
standard treatment is combination chemoradiotherapy with 4–6
courses of chemotherapy followed by radiotherapy to initial
disease sites (level of evidence C). Radiotherapy alone in these
patients is not recommended (level of evidence B). The reduction
of toxicity should be a primary end-point in trials evaluating novel
combination treatment modalities. 
Stage IIIB and IV disease 
Standard treatment is 6–8 courses of combination chemotherapy
(level of evidence B) (Figures 3 and 5). Radiotherapy has not been
shown to confer any extra benefit over chemotherapy alone (level
of evidence C). There is insufficient evidence to define the place of
intensification therapy for patients with stage IV disease. The
inclusion of patients in randomized trials is recommended.
Subsequent treatment of stages IIIB and IV disease is determined
according to the response to chemotherapy. If induction chem-
otherapy results in a complete remission, the options are no 
additional radiotherapy and radiotherapy to original sites of large-
volume disease (level of evidence C). 
If 6–8 courses of induction chemotherapy have only resulted in
a partial remission (greater than 50% response) and in the absence
of progressive visceral involvement, irradiation limited to the
residual masses is optional (level of evidence C). 
The inclusion of these patients in therapeutic trials is recom-
mended, to clarify the role of intensification therapy. 
If the response after 6–8 courses of induction chemotherapy is
less than 50% or if there is progressive disease, standard treatment
consists of ‘salvage’ treatment with non-cross resistant chemo-
therapy, with or without intensification therapy using haemato-
poietic stem cell rescue and radiotherapy (level of evidence 
C). The inclusion of patients in therapeutic trials is recom-
mended. 
Recurrent disease 
There is insufficient evidence to define clearly the best treatment
for recurrent HD. In the sub-group of bad-prognosis patients
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chemotherapy is at least equivalent, if not better, than conventional
chemotherapy (level of evidence C). The use of peripheral stem
cells and growth factors has reduced the toxicity of intensification
(level of evidence B). The treatment of recurrent disease must take
into consideration the initial treatment, the duration of complete
remission, the stage at recurrence and the age of the patient (level
of evidence C). 
The use of conventional chemotherapy (with or without radio-
therapy) can be considered for the following patients: 
l those initially treated with only radiotherapy or MOPP
chemotherapy (level of evidence C) 
l those with a localized recurrence who have been in complete
remission for more than 12 months (level of evidence C) 
l those greater than 65 years in age. 
In the other cases, an intensification regimen with haematopoietic
stem cell rescue is recommended (level of evidence C). This
should be undertaken after salvage with second-line chemo-
therapy. No one conditioning regimen has proven superiority over
any other (level of evidence C). It is recommended that any non-
irradiated initial disease site is irradiated following the stem cell
graft. Patients should be entered into therapeutic trials to clarify
the indications for intensification therapy. 
FOLLOW-UP 
Follow-up during treatment is based on clinical examination,
chest X-ray (CXR) and CT scan (standard). Gallium scanning is
recommended for the evaluation and surveillance of residual
mediastinal masses (level of evidence B). The place of PET 
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Strategy I-II supradiaphragmatic Hodgkins disease
Prognostic factors?





no systemic symptoms (A) and ESR < 50 or
systemic symptoms (B) and ESR < 30
and
without large-volume disease(X)




no systemic symptoms (A) and ESR ‡ 50
or




chemotherapy (3-4 months) + irradiation of
all initially involved areas (36 GY)
Standard
chemotherapy (6 months) + irradiation of
all initially involved areas (36 Gy)
Follow-up Follow-up
Figure 1 Treatment of clinical stage I–II supradiaphragmatic Hodgkins disease 
Standard
six courses of chemotherapy + irradiation of
all initially involved areas (36 Gy)
Follow-up
Stage I-II Hodgkins disease below the diaphragm
Figure 2 Treatment of stage I–II disease below the diaphragm Hodgkins disease 59
British Journal of Cancer (2001) 84 (Supplement 2), 55–60 © 2001 FNCLCC
Advanced stage Hodgkins disease















Figure 3 Treatment of advanced stage Hodgkins disease 
Stage IIIA unfavourable prognostic factors:
• male sex
• age > 50 years
• ‡ 4 nodal areas involved
• abdominal extension (III1 vs III2)





four courses of chemotherapy + irradiation
to all initially involved areas
or
chemotherapy alone (6 courses ) in the
case of early CR
Standards
4-6 courses of chemotherapy + 
irradiation to initially involved areas
or
chemotherapy alone (6-8 courses)
in the case of early CR
Follow-up Follow-up
no yes
Figure 4 Treatment of stage IIIA disease scanning (using fluorodesoxyglucose (FDG)) in the assessment of
response to therapy is under evaluation. MRI is not recommended
in routine practice. In the absence of complications, clinical
surveillance can be monthly during treatment. The frequency of
chest X-rays and CT scans is adapted to treatment and clinical
indication. 
The best methods and frequency of follow-up, or the indications
for investigations, have not been evaluated. The frequency recom-
mended by the Costwolds Meeting is one consultation every 3
months during the first and second years, every 4 months during
the third year and every 6 months during the fourth and fifth years,
then each year. This pattern has been adapted for the follow-up of
patients after treatment in clinical trials. It consists of a clinical
examination, full blood count including platelet count, ESR and a
CXR in the case of initial mediastinal involvement. CT scanning is
used for the follow-up of patients having focal residual disease
above or below the diaphragm, clinical suspicion or blood test
abnormalities (option). Late sequelae after treatment (cardiac,
respiratory, endocrine, etc) should be anticipated and prospec-
tively evaluated (standard). 
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Advanced stage IIIB-IV Hodgkins disease
Induction chemotherapy
6 courses
Evaluation of response after 4-6 courses
Complete remission Partial response (‡ 50%)
with residual mass
Response <50% progressive
disease or no response
Standard
there is no standard
Options
• consolidation: 2 courses of
   chemotherapy
• irradiation of initial sites of
   large volume disease 
Standard
there is no standard
Options
• irradiation of residual mass
• consolidation: 2 courses of




local irradiation after salvage therapy
Follow-up Follow-up Follow-up
Figure 5 Treatment of stages IIIB and IV disease 